Tarceva maintenance therapy in non-small cell lung cancer
Chomping at the bit, like many others today, to hear how the FDA ODAC meeting goes on regarding Tarceva maintenance therapy in lung cancer.
The initial OSI company presentation appeared to go well, but Q&A session did not; the committee clearly had concerns about the statistics. The SATURN data in adenocarcinoma was not as impressive as hoped, with the overall survival benefit being one extra month as opposed to taking the drug second line after initial chemotherapy failing and then getting 3 months of extra benefit with either Tarceva or docetaxel. Sometimes waiting and recovering will get you better results.
We posted about the original trial designs earlier this year in February and the initial results from the May ASCO meeting.
More at around 3pm ET today.
{UPDATE: ODAC VOTING 1 YES, 12 NO}